Traws Pharma, Inc. — Revenue by Fiscal Year
15 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/837729e5-bae0-4d30-bfc4-133f0aaa802f/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $2.8M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-043832 |
| FY 2024 | $226.0k | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-004165 |
| FY 2023 | $226.0k | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-004525 |
| FY 2022 | $226.0k | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-005107 |
| FY 2021 | $226.0k | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-004015 |
| FY 2020 | $231.0k | 2020-01-01 – 2020-12-31 | evidence 0001104659-21-038452 |
| FY 2019 | $2.2M | 2019-01-01 – 2019-12-31 | evidence 0001047469-20-001878 |
| FY 2018 | $1.2M | 2018-01-01 – 2018-12-31 | evidence 0001047469-19-001839 |
| FY 2017 | $787.0k | 2017-01-01 – 2017-12-31 | evidence 0001047469-18-001777 |
| FY 2016 | $5.5M | 2016-01-01 – 2016-12-31 | evidence 0001047469-17-002146 |
| FY 2015 | $11.5M | 2015-01-01 – 2015-12-31 | evidence 0001047469-16-011628 |
| FY 2014 | $800.0k | 2014-01-01 – 2014-12-31 | evidence 0001047469-15-002952 |
| FY 2013 | $4.8M | 2013-01-01 – 2013-12-31 | evidence 0001047469-14-002718 |
| FY 2012 | $46.2M | 2012-01-01 – 2012-12-31 | evidence 0001047469-14-002718 |
| FY 2011 | $1.5M | 2011-01-01 – 2011-12-31 | evidence 0001047469-14-002718 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Traws Pharma, Inc. — all facts · Net Income · Operating Income